Research and Markets: Pharma Company Lilly Has Developed a Strong Product Portfolio with Five Blockbuster Products with Sales In Excess Of US$1 Billion.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41405) has announced the addition of Espicom Business Intelligence's Eli Lilly Prospects to 2010 to their offering. Lilly focuses its research on six core therapeutic areas including neuroscience, cancer and infectious diseases. This report provides a full review of the company's activities together with sales forecasts for key products to 2010. Lilly is headquartered in the US and has approximately 42,000 employees worldwide. It markets its products in 158 countries and has research and development facilities in nine countries. Current Growth Drivers Lilly has developed a strong product portfolio with five blockbuster products with sales in excess of US$1 billion. The following products will form the basis of Lilly's short term growth: Zyprexa (olanzapine) is a thienobenzodiazepine antipsychotic antipsychotic /an·ti·psy·chot·ic/ (-si-kot´ik) effective in the treatment of psychotic disorders; also, an agent that so acts. Antipsychotics are a chemically diverse but pharmacologically similar class of drugs; besides psychotic with a unique receptor-binding profile indicated for the treatment of schizophrenia The concept of a cure as such in the treatment of schizophrenia remains controversial, as there is no consensus on the definition of "treatment" in the case of schizophrenia, although some criteria for the remission of symptoms have recently been suggested. and related conditions. In 2005, it remained Lilly's top selling product with sales in excess of US$4 billion. Cymbalta (duloxetine) a selective serotonin and norepinephrine reuptake inhibitor Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the central nervous system by inhibiting its reuptake from the , indicated for depression, stress urinary incontinence stress urinary incontinence n. See stress incontinence. and diabetic peripheral neuropathic pain. Evista (raloxifene) is a selective oestrogen oes·tro·gen n. Variant of estrogen. oestrogen see estrogen. receptor modulator Modulator Any device or circuit by means of which a desired signal is impressed upon a higher-frequency periodic wave known as a carrier. The process is called modulation. The modulator may vary the amplitude, frequency, or phase of the carrier. principally indicated for the treatment of postmenopausal post·men·o·paus·al adj. Of or occurring in the time following menopause. postmenopausal Change of life Gynecology adjective Referring to the time in ♀ when menstrual periods stop for ≥ 1 yr osteoporosis. Humalog (insulin lispro) is a recombinant analogue of human insulin human insulin n. A protein that has the normal structure of insulin produced by the human pancreas but that is prepared by recombinant DNA techniques and by semisynthetic processes. used in the treatment of diabetes. Gemzar(gemcitabine) is a cytarabine analogue, developed by Lilly for the treatment of non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. , pancreatic and other types of cancer. Alimta (pemetrexed disodium) is a multi-targeted antifolate that inhibits several enzymes in the biochemical pathways of folate folate /fo·late/ (fo´lat) 1. the anionic form of folic acid. 2. more generally, any of a group of substances containing a form of pteroic acid conjugated with l-glutamic acid and having a variety of substitutions. metabolism, which disturb a cancer cell's machinery and prevent it from multiplying. Key Late-Phase Products Reaching the Market Place Byetta (exenatide) is the first in a new class of drugs for the treatment of Type II diabetes Type II diabetes Type II diabetes is the most common form of diabetes and usually appears in middle aged adults. It is often associated with obesity and may be delayed or controlled with diet and exercise. Mentioned in: Diabetic Ketoacidosis called incretin mimetics and exhibits many of the same effects as the human incretin hormone, glucagon-like peptide-1. It was launched in the US in June 2005. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. This company report provides Latest Results A brief review of the latest report results Executive Summary At a glance understanding of the major trends and events affecting the company Financial Analysis (current year) Detailed P&L and investment review of the latest full year performance Company Strategy Where's the company going and how does it plan getting there? Product/R&D Pipeline Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available Appendices 5-year financial assessment Key agreements Infrastructure Key pharmaceutical subsidiaries/joint ventures Product index The Products Mentioned inside report include: Byetta Alimta Gemzar Humalog Evista Cymbalta Zyprexa For more information visit http://www.researchandmarkets.com/reports/c41405 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion